Danaher DHR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales by Business | ||||||
| Biotechnology | $7.48B+9.2% | $7.29B+7.9% | $7.13B+7.2% | $6.98B+4.9% | $6.85B+0.2% | |
| Diagnostics | $9.91B+2.1% | $9.94B+1.6% | $9.86B-0.1% | $9.76B0.0% | $9.71B-0.2% | |
| Life Sciences | $7.39B+1.7% | $7.33B+0.1% | $7.28B+0.7% | $7.27B+1.7% | $7.26B+1.2% | |
| Segment Reporting, Other Segment Item, Amount by Business | ||||||
| Biotechnology | $4.36B+7.7% | $4.29B+5.7% | $4.18B+4.6% | $4.1B+1.6% | $4.05B-0.8% | |
| Diagnostics | $6.69B+1.9% | $6.68B+2.2% | $6.65B+4.6% | $6.62B+3.5% | $6.56B+1.3% | |
| Life Sciences | $5.61B+3.1% | $5.58B+1.7% | $5.51B+2.7% | $5.47B+1.8% | $5.44B+1.4% | |
| Operating Income (Loss) by Business | ||||||
| Biotechnology | $1.96B+8.7% | $1.86B+10.6% | $1.83B+15.0% | $1.87B+15.4% | $1.8B+10.0% | |
| Diagnostics | $2.61B+3.7% | $2.65B+1.0% | $2.56B-7.4% | $2.51B-6.7% | $2.51B-1.8% | |
| Life Sciences | $544M-35.6% | $520M-40.8% | $560M-24.1% | $373M-63.3% | $845M-24.8% | |
| Identifiable assets by Business | ||||||
| Biotechnology | $148.89B— | $148.32B— | $145.58B— | —— | —— | |
| Depreciation by Business | ||||||
| Biotechnology | $155M+8.4% | $149M-1.3% | $148M-3.6% | $146M-7.6% | $143M-12.5% | |
| Diagnostics | $409M+3.0% | $407M+3.3% | $403M+4.2% | $397M+2.7% | $397M+4.1% | |
| Life Sciences | $188M+8.0% | $185M+10.8% | $181M+16.6% | $178M+24.0% | $174M+29.1% | |
| Capital expenditures, gross by Business | ||||||
| Biotechnology | $353M-17.1% | $370M-17.2% | $372M-14.3% | $395M-6.3% | $426M+2.7% | |
| Diagnostics | $621M+15.4% | $592M+7.6% | $565M+9.0% | $537M+2.1% | $538M+0.3% | |
| Life Sciences | $165M-56.5% | $186M-52.4% | $358M+47.9% | $370M+37.0% | $379M+26.3% | |
| Intangible Amortization by Business | ||||||
| Biotechnology | $923M+7.6% | $902M+4.5% | $885M+2.2% | $872M+0.9% | $858M-0.9% | |
| Diagnostics | $191M-0.5% | $191M-0.5% | $191M-1.8% | $192M-1.5% | $192M-2.3% | |
| Life Sciences | $607M+3.9% | $604M+4.9% | $601M+12.3% | $594M+19.9% | $584M+26.2% | |
| Goodwill by Business | ||||||
| Biotechnology | $92.6B+5.0% | $91.91B+4.8% | $90.04B+1.4% | $89.42B+1.7% | $88.16B+0.3% | |
| Diagnostics | $27.88B+1.9% | $27.76B+1.4% | $27.53B0.0% | $27.5B+0.4% | $27.36B-0.3% | |
| Life Sciences | $51.38B+3.6% | $51.08B+3.8% | $50.53B+2.8% | $50.4B+12.9% | $49.61B+21.5% | |
| Sales by Product | ||||||
| Nonrecurring revenue | $4.44B+0.1% | $4.44B-1.5% | $4.36B-3.0% | $4.35B-6.8% | $4.43B-9.9% | |
| Recurring revenue | $20.34B+4.9% | $20.13B+3.9% | $19.91B+3.4% | $19.67B+4.0% | $19.39B+3.0% | |
| Sales by Geography | ||||||
| High-growth markets | $7.11B+3.5% | $7.02B+2.2% | $6.91B+1.5% | $6.87B+0.5% | $6.87B-1.6% | |
| North America | $10.25B+0.1% | $10.36B+0.6% | $10.37B+0.6% | $10.25B+0.2% | $10.25B+1.0% | |
| Other developed markets | $1.26B+2.4% | $1.25B-0.1% | $1.25B+0.2% | $1.23B-1.2% | $1.23B-1.7% | |
| Western Europe | $6.16B+12.5% | $5.94B+8.8% | $5.74B+6.7% | $5.66B+7.7% | $5.48B+2.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Danaher break its business down?
- Danaher (DHR) reports sales by business across 3 parts — Biotechnology, Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Danaher's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Danaher's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
